Trial Profile
A prospective bioequivalence trial to evaluate the pharmacokinetics of Lisdexamfetamine (Vyvanse) chewable tablet in patients with attention deficit hyperactivity disorder, under fasting and non-fasting state
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2016
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 18 Apr 2016 New trial record
- 14 Apr 2016 According to a Shire media release, based on the results of 2 trials - SHP489-126 and SHP489-127, the company submitted a NDA to the US FDA for Lisdexamfetamine dimesylate (Vyvanse) as a chewable tablet for patients who may have difficulty swallowing or opening a capsule.